PBAC's latest decision on Aclidinium bromide: Recommended with restriction (2014). Considered for Long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Adult patients with stable moderate to severe chronic obstructive pulmonary disease (COPD), including those using aclidinium bromide as monotherapy, in combination with a long-acting beta agonist (LABA), or in combination with a LABA and an inhaled corticosteroid (ICS).
Therapy area
Respiratory
Line of therapy
Any
Evidence base
RCT
Primary endpoint
FEV1
Pivotal trial size
414 patients
Key trials
LAS-39, ACCORD, ATTAIN, ACCORD II
Comparator
tiotropium
Economic model
Cost-minimisation
Budget impact
$20M
Eligible patients/year
200,000
ICER note
Cost-minimisation analysis was used; no ICER calculated.